A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Respiratory Syncytial Virus Infections

In brief

The main purpose of this study is to investigate the antiviral effect of S-337395 compared with placebo among nonhospitalized adult participants with high-risk factors for progression to severe RSV infection starting intervention within 72 hours of RSV symptom onset.

Key facts

Study ID
NCT07214571
Run by
Shionogi
People needed
192
Starts
2025-12-11
Expected to finish
2026-12-30
Last updated by the study team
2026-07-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.